Results 61 to 70 of about 8,127 (167)

Clinical Advances in Breast Cancer: A Comprehensive Overview of Full‐Course Disease Management

Cancer Innovation, Volume 5, Issue 4, August 2026.
This review provides a comprehensive overview of clinical advances in breast cancer, highlighting subtype‐specific therapeutic paradigms. It underscores the full‐cycle integration of innovative therapies, as well as the growing role of biomarker‐guided strategies in advancing precision medicine.
Xuenan Peng, Yujing Tan, Fei Ma
wiley   +1 more source

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Breast, 2020
Purpose: In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and overall ...
Peter A. Fasching, J. Thaddeus Beck, Arlene Chan, Michele De Laurentiis, Francisco J. Esteva, Guy Jerusalem, Patrick Neven, Xavier Pivot, Giulia V. Bianchi, Miguel Martin, David Chandiwana, Brad Lanoue, Antonia Ridolfi, Yingbo Wang, Karen Rodriguez Lorenc, Arnd Nusch   +15 more
doaj   +1 more source

Ribociclib en el tratamiento del cáncer de mama localmente avanzado o metastásico. Eficacia y Seguridad.

, 2018
La combinación ribociclib más letrozol administrada en ciclos de 28 días a mujeres postmenopáusicas con cáncer de mama localmente avanzado o metastásico ER positivo HER 2 negativo, que no han sido tratadas anteriormente para la enfermedad avanzada, ha ...
Valle Corpas, Margarita, Ubago Pérez, Ruth   +1 more
core  

Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects

, 2020
Ribociclib, a selective and potent cyclin-dependent kinase 4/6 inhibitor, has demonstrated safety and efficacy in combination with endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer ...
Yan Ji, Yang, Shu, Tanay S. Samant, Rodriguez Lorenc, Cristina, Samant, Tanay, Ahmed M. Abdelhady, Ji, Yan, Abozeid, Ahmed M, Shu Yang, Karen Rodriguez Lorenc   +9 more
core   +1 more source

miR‐640 Enhances Abemaciclib Sensitivity by Suppressing CDK Inhibitor Resistance‐Associated Genes in Breast Cancer Cells

Journal of Cellular and Molecular Medicine, Volume 30, Issue 15, August 2026.
ABSTRACT We investigated the potential of miR‐640 to downregulate CDK4/6 inhibitor resistance‐associated genes and evaluated its apoptotic, anti‐metastatic and anti‐proliferative effects, both alone and in combination with abemaciclib in breast cancer cells. miR‐640 was identified via GSE126125 dataset analysis.
Ismail Mert Alkac, Cigir Biray Avci
wiley   +1 more source

An Improved Process for The Preparation of Ribociclib and its Salts

, 2019
The invention relates to a process for the preparation of ribociclib of formula V or its salts. The invention provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate.
Tiwari, H., G., M.K., Musmade, S.S., Dua, Shukla, Cabri W, Sokhi, Lahiri, Pandey, R.N., Singh, S.M., S.   +15 more
core   +1 more source

Molecular profiling of breast cancer pleural effusions using cytology specimens: Impact of sample source and cytological features on next‐generation sequencing performance

Cancer Cytopathology, Volume 134, Issue 7, July 2026.
ABSTRACT Background Malignant effusions in breast cancer are a minimally invasive source for molecular profiling. Effusion‐derived cytology specimens, cell blocks (CB) and post‐ThinPrep PreservCyt (PTPC) supernatant, are reliable sources for molecular testing but differ in DNA concentration and turnaround time (TAT).
Harpreet Virk, Claire Michael, Keri Ann Pfeil, Navid Sadri, Philip Bomeisl, Aparna Harbhajanka   +5 more
wiley   +1 more source

Eficacia relativa de Palbociclib y Ribociclib en el tratamiento de cáncer de mama localmente avanzado o metastásico: comparación Indirecta

, 2018
Se evalúa la eficacia relativa de palbociclib-letrozol y ribociclib-letrozol en mujeres postmenopáusicas con cáncer de mama avanzado ER positivo HER2 negativo que no habían recibido terapia sistémica previa para la enfermedad avanzada a través de ...
Valle Corpas, Margarita, Ubago Pérez, Ruth, Acosta García, Héctor   +2 more
core  

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer

Фармакоэкономика, 2020
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib and abemaciclib are the new treatment options for postmenopausal women with locally advanced or metastatic hormone-receptor (HR) positive human epidermal growth factor receptor 2
N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov   +2 more
doaj   +1 more source

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

, 2018
Gabriel Tremblay,1 David Chandiwana,2 Mike Dolph,1 Jaclyn Hearnden,1 Anna Forsythe,1 Mauricio Monaco2 1Purple Squirrel Economics, New York, NY, USA; 2Novartis Pharmaceutical Corporation, East Hanover, NJ, USA Background: Ribociclib (RIBO) and palbociclib
Hearnden J, Forsythe A, Tremblay G, Monaco M, Chandiwana D, Dolph M   +5 more
core